RxDoctor Payments Data

Vivian Cook, MD

Hematology & Oncology · Newburgh, INNPI 1386805307

Payments from drug & device makers

$2,971in general payments, 2019–2025

Across 56 payments — averaging $53.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$2K
  • Amgen$219
  • AstraZeneca$126
  • E.r. Squibb & Sons, L.L.C.$75
  • Johnson & Johnson$69
  • Exelixis Inc.$57
  • plus $507 from 20 others

What the payments were for

  • Food & beverage$78426%
  • Education$2689%
  • Gifts$1,91865%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,971 in reported general payments places this provider in the 30th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$201,699
Medicare patients
452
Services billed
6,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib18$273,184
RevlimidLenalidomide15$256,131
KisqaliRibociclib Succinate17$224,743
JakafiRuxolitinib Phosphate12$210,876
XtandiEnzalutamide15$180,042
EliquisApixaban84$69,302
XareltoRivaroxaban92$68,188
Abiraterone Acetate34$50,500
Imatinib Mesylate24$5,918
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen65$2,743
Anastrozole164$2,606
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$1,584
Letrozole80$1,328
Dexamethasone58$1,043
Hydroxyurea48$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$11$342,486102 claims
Bristol Myers SquibbRevlimid$31$256,13115 claims
NovartisKisqali$37$224,74317 claims
Astellas Pharma US IncXtandi$14$180,04215 claims
Johnson & JohnsonXarelto$69$68,18892 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$11$35040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 224 hematology & oncology providers in Indiana.

Other hematology & oncology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →